Support for the CONDUCT OF STUDIES TO EVALUATE THE IMPACT OF GENETIC BACKGROUND AND POTENTIAL TREATMENTS ON SEVERE SARS-CoV-2 INDUCED PNEUMONIA FOR THE NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIEN

Battelle Memorial Institute, Richland OH

Investigators

Abstract

COVID19 is a novel zoonosis which has the potential for severe complications. Approximately 20% of affected individuals develop severe pneumonia progressing to acute respiratory distress syndrome (ARDS). Complication rates increase with advanced age, and 6-15% of patients over 70 years die due to COVID19. Severe COVID19 is manifesting primarily as ARDS and respiratory failure, leading to high prevalence of prolonged intensive care utilization, and thus to overwhelmed medical facilities. Currently there is no proven treatment for COVID19 severe disease.